

## Meningococcal Vaccines

<b>Vaccine Description</b>	<ul style="list-style-type: none"> <li>• Brands: Menomune<sup>®</sup>, Menactra<sup>®</sup>, and Menveo<sup>®</sup></li> <li>• Inactivated, bacterial polysaccharide (Menomune<sup>®</sup>)</li> <li>• Inactivated, bacterial polysaccharide conjugate (Menactra<sup>®</sup> and Menveo<sup>®</sup>)</li> <li>• Contains thimerosal (only multidose Menomune<sup>®</sup>) and latex (stopper only for Menactra<sup>®</sup>)</li> <li>• See package insert</li> </ul>	
<b>Dose &amp; Route</b>	<ul style="list-style-type: none"> <li>• Dose: 0.5 mL</li> <li>• Route: SC (Menomune<sup>®</sup>) and IM (Menactra<sup>®</sup> and Menveo<sup>®</sup>) (Precaution: hemophilia, thrombocytopenia, and anticoagulation therapy)</li> <li>• See package insert</li> </ul>	
<b>Indications</b>	<ul style="list-style-type: none"> <li>• All children at age 11 to 12 years and unvaccinated adolescents at subsequent visit</li> <li>• College freshmen living in dormitories</li> <li>• Children older than 2 years who:               <ul style="list-style-type: none"> <li>- have functional or anatomic asplenia</li> <li>- are traveling to or living in an endemic area</li> <li>- have certain immune system disorders</li> <li>- have been exposed to meningitis during an outbreak</li> </ul> </li> <li>• Menactra<sup>®</sup> or Menveo<sup>®</sup> are preferred, but Menactra<sup>®</sup> is only licensed for use in people 2 to 55 years of age and Menveo<sup>®</sup> in people 11 to 55 years of age</li> <li>• Menomune<sup>®</sup> may be given to children 3 months to 2 years if provider determines it is necessary</li> </ul>	
<b>Administration Schedule</b>	<b>Age</b>	<b>Dose</b>
	3 months to 2 years of age	2 doses of the age-appropriate vaccine, 3 months apart if indicated by the provider
	2 years or older	1 dose of the age-appropriate vaccine
<b>Booster</b>	<ul style="list-style-type: none"> <li>• Menomune<sup>®</sup> and Menactra<sup>®</sup>:               <ul style="list-style-type: none"> <li>• 5 years if 1st dose given at 7 years of age or older</li> <li>• 3 years if 1st dose given at 2 through 6 years of age</li> </ul> </li> <li>• Menveo<sup>®</sup>: unknown at this time</li> </ul>	

## Meningococcal Vaccines (*Continued*)

<b>Contraindications</b>	<ul style="list-style-type: none"><li>• Serious allergic reaction to prior dose or vaccine component, including latex (Menactra<sup>®</sup> stopper)</li><li>• Moderate or severe acute illness</li><li>• History of Guillain-Barré syndrome (Menactra<sup>®</sup>)</li><li>• Children younger than 11 years of age (Menveo<sup>®</sup>), 2 years of age (Menactra<sup>®</sup>) or 3 months of age (Menomune<sup>®</sup>)</li><li>• Adults older than 55 years of age (Menactra<sup>®</sup> or Menveo<sup>®</sup>)</li></ul>
<b>Special Considerations</b>	<ul style="list-style-type: none"><li>• Additional doses may be indicated for certain patients at continued risk</li><li>• Refer children 3 to 23 months to a provider to determine whether Menomune<sup>®</sup> should be given</li><li>• Menactra<sup>®</sup> is only licensed for use in people between the ages of 2 to 55 years</li><li>• Menveo<sup>®</sup> is only licensed for use in people between the ages of 11 to 55 years</li><li>• Menactra<sup>®</sup> and Menveo<sup>®</sup> have not been widely studied in pregnant women and should be given only if clearly indicated; OK to give Menomune<sup>®</sup></li><li>• There have been reports of Guillain-Barré syndrome (GBS) after Menactra<sup>®</sup>; post-marketing study of this continues</li></ul>
<p>VIS: <a href="http://www.cdc.gov/vaccines/pubs/vis/downloads/vis-mening.pdf">http://www.cdc.gov/vaccines/pubs/vis/downloads/vis-mening.pdf</a> Pregnancy registry for Menactra<sup>®</sup>: 1-800-822-2463 (sanofi pasteur); Pregnancy registry for Menveo<sup>®</sup>: 1-877-311-8972 (Novartis); also notify VHC Networks for long-term support and follow-up</p>	